Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients-Reference-Cited by-同舟云学术

Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients

Published:2016-08-12 Issue:5 Volume:13 Page:e212-e223
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Pan Szu-Hua¹²³,Su Kang-Yi⁴⁵⁶,Spiessens Bart⁷,Kusuma Nicole⁷,Delahaye Nicolas F⁷,Gruselle Olivier⁷,Myo Aung⁷,de Creus An⁷,Louahed Jamila⁷,Chang Gee-Cheng⁸⁹¹⁰,Yu Sung-Liang⁴⁵⁶,Yang Pan-Chyr⁴¹¹¹²

Affiliation:

1. Graduate Institute of Medical Genomics and Proteomics; College of Medicine; National Taiwan University; Taipei Taiwan

2. Genome and Systems Biology Program; National Taiwan University and Academia Sinica; Taipei Taiwan

3. Ph.D. Program in Translational Medicine; National Taiwan University and Academia Sinica; Taipei Taiwan

4. Center for Genomic Medicine; National Taiwan University; Taipei Taiwan

5. Department of Clinical Laboratory Sciences and Medical Biotechnology; College of Medicine; National Taiwan University; Taipei Taiwan

6. Department of Laboratory Medicine; National Taiwan University Hospital; Taipei Taiwan

7. GSK Vaccines; Rixensart Belgium

8. Institute of Biomedical Sciences; National Chung Hsing University; Taichung Taiwan

9. Division of Chest Medicine; Department of Internal Medicine; Taichung Veterans General Hospital; Taichung Taiwan

10. Faculty of Medicine; School of Medicine; National Yang-Ming University; Taipei Taiwan

11. Department of Internal Medicine; College of Medicine; National Taiwan University; Taipei Taiwan

12. Institute of Biomedical Sciences; Academia Sinica; Taipei Taiwan

Funder

GlaxoSmithKline Biologicals SA

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12586/fullpdf

Reference48 articles.

1. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer;Savas;J Thoracic Dis,2013

2. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies;Hojjat-Farsangi;Int J Mol Sci,2014

3. Activating mutations in the epidermal growth factor underlying responsiveness of non-small cell lung cancer to gefitinib;Lynch;N Eng J Med,2004

4. PharmGKB summary: very important pharmacogene information for epidermal growth factor receptor (EGFR);Hodoglugil;Pharmacogenet Genom,2013

5. Molecular pathways and therapeutic targets in lung cancer;Shtivelman;Oncotarget,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract;Diagnostics;2023-12-10

2. PReferentially Expressed Antigen in MElanoma Expression in Uterine and Ovarian Carcinosarcomas;International Journal of Gynecological Pathology;2023-11-13

3. Molecular and clinicopathological implications of PRAME expression in adult glioma;PLOS ONE;2023-10-05

4. Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target;International Journal of Translational Medicine;2023-08-29

5. Transcriptomic insights into adenoid cystic carcinoma via RNA sequencing;Frontiers in Genetics;2023-04-21